期刊文献+

VEGF和CD31在子宫内膜样腺癌中的表达及其临床意义 被引量:8

Expression and Clinical Significance of VEGF and CD31 in Eddometriod Carcinoma
暂未订购
导出
摘要 目的:检测血管内皮生长因子(VEGF)和CD31在不同子宫内膜组织中的表达情况。方法:采用免疫组化方法检测VEGF、CD31在52例子宫内膜样腺癌组织、22例子宫内膜不典型增生组织及21例正常子宫内膜组织中的表达,对结果进行量化分析。结果:(1)VEGF在正常子宫内膜组织、不典型增生组织及子宫内膜样腺癌中表达的阳性率分别为23.8%、31.8%、65.4%;CD31在正常子宫内膜组织、不典型增生组织及子宫内膜样腺癌组织中标记的微血管密度(microvessel density,MVD)分别为23.6±11.7、31.5±17.7、51.9±21.1。VEGF的阳性表达及CD31-MVD(CD31标记的MVD)在子宫内膜样腺癌组织中明显高于不典型增生及正常子宫内膜组织(P<0.05)。(2)VEGF在子宫内膜样腺癌中的表达,与淋巴结转移有关(P<0.05)。CD31-MVD与肿瘤分期、浸润肌层深度、组织学类型有关(P<0.05)。(3)在子宫内膜样腺癌组织,VEGF表达与CD31-MVD无明显相关性(r=0.095,P=0.504)。结论:VEGF表达、CD31-MVD在子宫内膜样腺癌组织中增高,可能促进子宫内膜样腺癌的发生发展及转移浸润。 Objective:To explore the expression of VEGF,CD31 in endometriod carcinoma. Methods:Expres- sion levels of VEGF and CD31 in 52 cases of endometriod carcinoma,22 cases of atypical hyperplasia and 21 ca- ses of normal endometrium tissues were analyzed by immunohistochemistry,and the blood vessels stained with CD31 were counted. Results:(1)The positive rate of VEGF expression in normal endometrium,atypical hyperplasi- a and endometriod carcinoma was 23, 8% ,31.8% ,65.4% respectively. The CD31 - MVD was significantly differ- ent in normal endometrium, atypical hyperplasia and endometrial carcinoma, which were 23. 6 ± 11.7,31.5 ± 17. 7,51.9 ±21.1 respectively. (2)The expression of VEGF was correlated with lymphatic metastasis( P〈0. 05). The CD31 -MVD was correlated with tumor stage, myometrial invasion and histological grade (P 〈 0.05). (3)There was no correlation of VEGF and CD31 expression in endometriod carcinoma tissues ( r = 0. 095, P = 0. 504). Conclusions:The over-expression of VEGF and CD31 may participate in angiogenesis of endometriod carcinoma, This research shows that they have clinical value as the tumor markers of endometriod carcinoma,
作者 夏秀红 范江涛 李莉莉 陈红燕 XlA Xiuhong;FAN Jiangtao;LI Lili;et al(The First Affiliated Hospital of Guangxi Medical University, Nanning Guangxi 530021, China)
出处 《实用妇产科杂志》 CAS CSCD 北大核心 2018年第4期282-286,共5页 Journal of Practical Obstetrics and Gynecology
基金 国家自然科学基金(编号:81360388) 广西自然科学基金(编号:2016 GXNSFAA380258)
关键词 子宫内膜样腺癌 血管生成 血管内皮生长因子 CD31 Endometriod carcinoma Angiogenesis Vascular endothelial growth factor CD31
  • 相关文献

参考文献2

二级参考文献31

  • 1张江宇,王颀,张雅洁.CD105与肿瘤关系的研究进展[J].中华肿瘤防治杂志,2007,14(18):1433-1436. 被引量:4
  • 2Jemal A,Siegel R,Ward E,et al.Cancer statistics,2008[J].CA Cancer J Clin,2008,58(2):71-96.
  • 3Kononen J,Bubendorf L,Kallionieni A,et al.Tissue microarrays for high-throughput molecular profiling of tumor specimens[J].Nature Med,1998,4(7):844-7.
  • 4Mahipal A,McDonald M J,Witkiewicz B I,et al.Epidermal growth factor receptor overexpression in resected pancreatic cancer[J].J Clin Oncolo,2011,29(S4):317.
  • 5Weidner N.Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors[J].Breast Cancer Res Treat,1995,36(2):169-80.
  • 6Tabernero J.The role of VEGF and EGFR inhibition:implications for combining anti-VEGF and anti-EGFR agents[J].Mol Cancer Res,2007,5(3):203-20.
  • 7Lutz M P,Esser I B,Flossmann-Kast B B,et al.Overexpression and activation of the tyrosine kinase Src in human pancreatic carcinoma[J].Biochem Biophys Res Commun,1998,243(2):503-8.
  • 8Ueda S,Ogata S,Tsuda H,et al.The correlation between cytoplastic overexpression of epidermal growth factor receptor and tumor aggressiveness:poor prognosis in patients with pancreatic ductal adenocarcinoma[J].Pancreas,2004,29(1):1-8.
  • 9Rivera F,Lopez-Tarruella S,Vega-Villegas M E,et al.Treatment of advanced pancreatic cancer:from gemcitabine single agent to combinations and targeted therapy[J].Cancer Treat Rev,2009,35(4):335-9.
  • 10Nagaraj N S,Washington M K,Merchant N B.Combined Blockade of Src kinase and Epidermal Growth Factor Receptor with Gemcitabine Overcomes STAT3-Mediatde Resistance of inhibition of Pancreatic Tumor Growth[J].Clin Cancer Res,2011,17(3):483-93.

共引文献17

同被引文献72

引证文献8

二级引证文献90

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部